DNA Chip Research Inc. (TYO:2397)

DNA Chip Research Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	1,091	490	327	427	324
Revenue Growth (YoY)	122.65%	49.85%	-23.42%	31.79%	-10.25%
Cost of Revenue	521	424	363	339	258
Gross Profit	570	66	-36	88	66
Selling, General & Admin	530	255	262	191	173
Research & Development	-	69	65	64	65
Operating Expenses	530	324	327	255	238
Operating Income	40	-258	-363	-167	-172
Currency Exchange Gain (Loss)	-	-	-	-1	-
Other Non Operating Income (Expenses)	-	11	-2	28	-3
EBT Excluding Unusual Items	40	-247	-365	-140	-175
Asset Writedown	-9	-	-4	-10	-
Other Unusual Items	-87	-	8	16	3
Pretax Income	-56	-247	-361	-134	-172
Income Tax Expense	2	1	1	-	-
Net Income	-58	-248	-362	-134	-172
Net Income to Common	-58	-248	-362	-134	-172
Shares Outstanding (Basic)	7	6	6	6	6
Shares Outstanding (Diluted)	7	6	6	6	6
Shares Change (YoY)	6.40%	8.33%	1.33%	1.99%	11.53%
EPS (Basic)	-8.58	-39.02	-61.70	-23.15	-30.30
EPS (Diluted)	-8.58	-39.02	-61.70	-23.15	-30.30
Free Cash Flow	38	-147	-430	-79	-85
Free Cash Flow Per Share	5.62	-23.13	-73.29	-13.64	-14.97
Gross Margin	52.25%	13.47%	-11.01%	20.61%	20.37%
Operating Margin	3.67%	-52.65%	-111.01%	-39.11%	-53.09%
Profit Margin	-5.32%	-50.61%	-110.70%	-31.38%	-53.09%
Free Cash Flow Margin	3.48%	-30.00%	-131.50%	-18.50%	-26.24%
EBITDA	97	-217	-346	-151	-151
EBITDA Margin	8.89%	-44.29%	-105.81%	-35.36%	-46.61%
D&A For EBITDA	57	41	17	16	21
EBIT	40	-258	-363	-167	-172
EBIT Margin	3.67%	-52.65%	-111.01%	-39.11%	-53.09%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.